Loading stock data…
Viridian Therapeutics, Inc. (VRDN)
$18.79+0.89 (+4.97%)
After Hours$18.70-0.09 (-0.48%)· Last close Jun 29
Viridian Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $18.79 with a market capitalization of $1.8B. Wall Street consensus targets $35.50 (16 analysts), implying a +88.9% move over the next 12 months. The stock is currently 45% below its 52-week high of $34.29, remaining 22.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +88.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $141,000↑ | $132,000↓ | $70.57M↑ | $75,000↑ | $72,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$116.17M↑ | -$122.75M↓ | -$40.01M↑ | -$106.77M↓ | -$93.87M |
| Net Income | -$104.90M↑ | -$120.36M↓ | -$34.60M↑ | -$100.73M↓ | -$86.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.70%
Volume
Today's trading volume
7.59M
Recent News
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1%, and the actively trade
Comcast, Viridian Therapeutics jump premarket; Doximity slips
Investing.com - U.S. stock futures rose on Monday as investors assessed reports that Washington and Tehran had agreed to halt recent hostilities around the Strait of Hormuz and resume diplomatic talks, easing fears of broader disruptions in the Middle East.
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease.
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced stocks to buy for the next 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gross proceeds. The financing consists of $225 million in 1.75% convertible senior notes due 2032 and an equity […]
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.